pros and cons of semaglutide vs tirzepatide vs. for Weight Loss Tirzepatide vs. Semaglutide: Which Weight

Description

Depending on meeting the criteria, a drug may receive FDA expedited program guidance, accelerated review, and/or Accelerated Approval

A 28-day phase 1 MAD study was conducted in participants who were overweight or obese, revealing mean weight loss of 0.6%, 2.5%, 4.4%, and 5.5%, corresponding to groups administered placebo, 240 mg, 500 mg, and 740 mg (54)

That model leads to rising pharmacy spend , poor long-term outcomes , and an employee population dependent on a drug they cant afford to stop

Wilson, J

An effective glucagon-like peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism